



Unlocking the Previously “Undruggable”

September 22-23, 2020 | EDT Timezone

The Undruggable Leaders Forum has been re-engineered to be a dynamic learning experience. Working with industry leaders, attendees will be able to access **even more high quality content and networking opportunities than before**, all from the comfort of their own home.

Through a more personalized and flexible experience, attendees will be able to participate in **engaging live discussions**, actively or passively take part in **roundtables**, instantly **message fellow attendees**, join a variety of **networking sessions** and much more. Oh, and not to mention the rockstar speaker faculty and crucial topics on the agenda.

With the recent changes in drug discovery and development, it is now more crucial than ever to **unlock more areas of undruggability** to deliver the next generation of therapies.

Networking Available All Day

9:00am - 5:00pm - Day 2, Tuesday, September 22

9:00am - 1:15pm - Day 3, Wednesday September 23

As the main agenda progresses throughout the day, you will have the choice of listening in to / participating in the live content or spend more of your time networking with your peers.

Here is how you will be able to achieve this, outside of the networking sessions on the agenda

- **See who's in the room** - you will be able to message all live attendees and connect with those who respond.
- **Schedule 1-2-1 video calls** with your connections at any time that suits you.
- **Open Networking** - think of this as the event lobby where you can replicate those all-important "water-cooler" moments.

You will be able to hop seamlessly between networking and on-going agenda sessions at any point.

With networking available all day, this will provide you with even more opportunities to meet your potential future partners and collaborators.

Day 1: Tuesday, September 22, 2020

Location: **Stage**

8:00am Conference Platform Opens

The conference platform opens before the agenda starts, giving you time to plug the presentations, panels and discussions into your agenda for the rest of the day. This also gives you plenty of time to get familiar with the platform.

9:00am Chair's Opening Remarks & Setting the Scene

Adrian Gill, Senior Vice President, Chemistry, [Revolution Medicines](#)

9:10am Case Study: Unlocking the "Undruggable" by Targeting Protein Degradation

Nello Mainolfi, Founder, President & Chief Executive Officer, [Kymera Therapeutics](#)

9:30am Wellness Break

Get-up and have a stretch before the next session begins.

Location: **Sessions**

9:35-10:25am Keynote Panel & Interactive Q&A - **Defining the “Undruggable” Landscape**

With two days ahead filled with all things “undruggable”, defining the major challenges and opportunities in this space is where we start. This panel of industry experts will examine these leading challenges and opportunities and share their lessons learned so far.

- What crucial gaps in our current scientific understanding do we need to fill to maximize the chances of clinical success?
- What are the common challenges that bind us together as an industry?
- What lessons are we learning from the partnerships being struck in this space?
- What needs to happen next for approaches targeting “undruggable” targets to reach their potential?
- What do we hope to learn by bringing this industry together?

Robert Konrat, Professor of Biomolecular Structural Chemistry, [University of Vienna](#)

Sandra Glucksmann, President and Chief Executive Officer, [Cedilla Therapeutics](#)

Nello Mainolfi, Founder, President & Chief Executive Officer, [Kymera Therapeutics](#)

Laura Towart, Founder & Chief Executive Officer, [My Personal Therapeutics](#)

10:05am **Optional Break**

Catch-up on emails, let the dog out, brew some more coffee... use this time to take care of regular day-to-day life.

Location: **Sessions**

10:05am **Open Q&A with Speakers**

This is your chance to pose your burning questions to the expert speakers from the previous panel.

Actively or passively take part in this session.

Robert Konrat, Professor of Biomolecular Structural Chemistry,
University of Vienna

Sandra Glucksmann, President and Chief Executive Officer, **Cedilla
Therapeutics**

Nello Mainolfi, Founder, President & Chief Executive Officer, **Kymera
Therapeutics**

Laura Towart, Founder & Chief Executive Officer, **My Personal
Therapeutics**

Location: **Networking Area**

10:25am **Speed Networking**

In the purpose-built Networking area, get ready to expand your network through randomly assigned 1 on 1 quick-fire video meetings. You can choose who you want to “connect” with and then set-up 1-2-1 in-depth catch-up’s throughout the rest of the event.

This function also ensures that you don’t meet the same person more than once, allowing you to meet as many fellow attendees as you desire.

Your future collaborators or partners could be just one click away!

Location: **Stage**

10:45am Case Study – **Cellular strategies for assessing degradability and selectivity of key therapeutic targets**

- Use of HaloPROTAC3 to determine target protein degradation capability via E3 ligase recruitment and protein loss phenotype of undruggables
- Real-time cellular degradation study and selectivity profiles of a panel of 16 CDK family members in response to a pan-kinase PROTAC
- Mechanistic understanding of cell cycle dependent protein loss of CDK2 by a degrader compound

Danette L. Daniels, R&D Group Leader, *Promega Corporation*



11:10am Wellness Break

Get-up and have a stretch before the next session begins.

11:15am Case Study - **Leading the Development of RNA-Targeted Therapeutics: Lessons from Success**

- Hear about Ionis Pharmaceuticals' antisense technology platform has birthed more than 40 first-in-class/best-in-class medicines treating cancer, cardiovascular, neurological, infectious and pulmonary diseases with the majority in Phase II/III
- A look at how Ionis have worked to optimise their antisense technology, which overcomes common undruggable problems, such as routes of delivery, tissue targeting, and frequency and strength of dosages
- Lessons learned from creating the world's first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis

Shuling Guo, Vice President, Antisense Drug Discovery, [Ionis Pharma](#)

11:35am Wellness Break

Get-up and have a stretch before the next session begins.

11:40am Case Study - **Presentation by Accent Therapeutics**

- RNA modifying proteins (RMPs) represent a large class of novel targets for oncology and other disease indications that can be targeted with small molecule inhibitors
- Accent has prioritized drug discovery efforts on several RMPs:
- METTL3, an m⁶A RNA methyltransferase implicated in AML and multiple solid tumor indications
- ADAR1, an adenosine deaminase important for cell lines and tumors displaying endogenous elevated Type1 IFN signaling

Ann Boriack-Sjodin, Vice President, Molecular Discovery, [Accent Therapeutics](#)

12:00pm Wellness Break

Get-up and have a stretch before the next session begins.

12:05pm Case Study - **Targeting Undrugged Oncogenic Mutations Across Tumor Types**

- Hear how Black Diamond Therapeutics use their Mutation-Allostery-Pharmacology, or MAP, platform to target undrugged driver mutations in genetically defined cancers
- Discussion will include how the MAP platform uses genetic and proteomic features to rank mutations found from population-level genetic sequencing for potential oncogenicity, and how these mutations are then grouped into mutation subsets using cell and

tumour models

- A look at how single small molecule kinase inhibitors are then designed for each subset, and their current preclinical pipeline targeting EGFR and HER2 mutants

Elizabeth Buck, Co-Founder, EVP, Discovery & Translational Sciences, **Black Diamond Therapeutics**

Location: **Expo**

12:25pm **Tour of Expo**

Take a look around the virtual Expo and interact with the partners of the Undruggable Leaders Forum to learn more about their services.

12:45pm

Lunch

Finally, a lunch at a conference that is completely your choice!

Use this extended break to have your regular lunch, spend time with your family and give your brain a break. Recharge for the afternoon session.

Day 1 of The Undruggable Leaders Forum includes an extended break in the middle to give you ample time for lunch and another chance to catch-up on the day job. Or if you have time, you can use this break for 1-2-1 meetings or open networking.

Location: **Stage**

2:00pm Presentation - Presentation by Cyclica TBA



Representative from Cyclica

Benjamin DiFrancesco, Applied Scientist, Cyclica and Igor Stagljar, Professor, University of Toronto

2:25pm Wellness Break

Get-up and have a stretch before the next session begins.

2:30pm Case Study - **The Potential for CPMPs to Overcome the Limitations of Traditional Drugs**

- Combining broad target coverage with cell-penetrating ability, raising the prospect of universal druggability
- Discussion of why alpha helical structure is a beneficial feature of CPMPs
- Overview of the FogPharma platform for scalable, rapid discovery of Helicon™ Peptides
- Helicon™ peptide discovery case study

Howard Stern, Chief Scientific Officer, **FogPharma**

2:55pm Wellness Break

Get-up and have a stretch before the next session begins.

Location: **Sessions**

3:00pm Open Discussion - **Investing into the Undruggable**

- An overview of Pfizer Venture's investment strategy
- Focus on the undruggable landscape and why certain companies were committed to
- Open discussion with the audience on the investment opportunities undruggable work is presenting

Chris O'Donnell, Executive Director & Principal, **Pfizer Ventures**

3:20pm Wellness Break

Catch-up on emails, let the dog out, brew some more coffee... use this time to take care of regular day-to-day life.

Location: **Sessions**

3:45pm-4:15pm: Panel Discussion & Interactive Q&A - **Partnering with Pharma: Building Relationships to Unlock the Undruggable**

With pharmaceutical companies driving much of the industry's success, either from buying or building, key questions are emerging on how these companies view the industry, and which approach is best. Tap into the mind of senior decision makers in the key pharmaceutical companies to hear their thoughts on the following:

- In general, how do pharmaceutical companies view the undruggable industry?
- How is risk assessed, and when is the right time in the maturation of a field to get involved?
- Pros and cons of in-house development vs strategic collaborations?
- What lessons are being learned from partnerships in this space?
- What are pharma looking to identify when partnering with biotechs targeting the "undruggable"?

Garrett Rhyasen, Senior Director of Search & Evaluation, Global Business Development & Licensing, Oncology R&D, **AstraZeneca**

Markus Haerberlein, Vice President, Head of Discovery, **Alkermes**

Howard Stern, Chief Scientific Officer, **FogPharma**

Location: **Networking & Sessions**

4:15pm - 5:00pm **Virtual Drinks**

Share a virtual drink with old friends or new connections. This is your chance to casually interact with the rest of the Undruggable industry.

Location: **Sessions**

4:15pm - 4:35pm **Open Q&A with Speakers**

This is your chance to pose your burning questions to the expert speakers from the previous panel.

Actively or passively take part in this session.

Garrett Rhyasen, Senior Director of Search & Evaluation, Global Business Development & Licensing, Oncology R&D, **AstraZeneca**
Markus Haerberlein, Vice President, Head of Discovery, **Alkermes**
Howard Stern, Chief Scientific Officer, **FogPharma**

Day 2: Wednesday, September 23, 2020

Location: **Stage**

8:00am Conference Platform Opens

The conference platform opens an hour before the sessions begin so that you can plug the presentations, panels and discussions into your calendar for the day ahead.

9:00am Chair's Opening Remarks

Adrian Gill, Senior Vice President, Chemistry, [Revolution Medicines](#)

Location: **Sessions**

9:10am Fireside Chat - Moderna Therapeutics: Unlocking the "Undruggable" Through mRNA

- What promise do mRNA medicines hold for targeting "undruggable" targets?
- What disease states are showing the most promise so far?
- What is the vision for Moderna Therapeutics?

Stéphane Bancel, Chief Executive Officer, [Moderna, Inc.](#)

9:25am Open Q&A with Stéphane Bancel, Chief Executive Officer, [Moderna, Inc](#)

9:45am Wellness Break

Get-up and have a stretch before the next session begins

Location: **Stage**

9:50am Presentation - Presentation by Atomwise TBA



Abe Heifets, CEO & Co-Founder, [Atomwise](#)

10:15am Wellness Break

Get-up and have a stretch before the next session begins

10:20am Case Study - **Small Molecule Microarray Technology and Transcription Factor Modulators**

Angela Koehler, Scientific Founder/Associate Professor, [Kronos Bio/Koch Institute for Integrative Cancer Research \(MIT\)](#)

10:40am Wellness Break

Get-up and have a stretch before the next session begins

10:45am Case Study - **Modulating Protein Expression Through RNA-Targeted Small Molecules (rSMs)**

- Hear how rSMs can increase or decrease protein expression through disrupting processing, transport, stability or translation of encoding RNAs
- A look at Arrakis' proprietary rSM platform, which utilises their exclusive technologies TRYST, MARS and PEARL-Seq to identify rSMs on an industrial scale
- Discussion will focus on how this approach has potential to address the entire human transcriptome, with opportunity in treating a multitude of diseases including cancer

Jennifer Petter, Founder and Chief Scientific Officer, [Arrakis Therapeutics](#)

11:05am Wellness Break

Catch-up on emails, let the dog out, brew some more coffee... use this time to take care of regular day-to-day life.

Location: **Stage**

Location: **Sessions**

11:30am Case Study - **Translating Frontier Cancer Targets**

- Overview of Revolution Medicines differentiated innovation engine to drug a diverse range of frontier cancer targets, including allosteric modulation of SHP2 phosphatase and the

11:30am Interactive Roundtable - **Protecting Innovation when Unlocking the Undruggable**

This interactive, discussion-led session will enable you to deepen your understanding of Intellectual Property. Share your insights, pose your

identification of RMC-4630

- Proprietary tri-complex technology approach to targeting oncogenic RAS(ON) mutants
- Discovery of novel bi-steric compounds with dual modes of action to selectively target mTORC1 (identification of RMC-5552)

Rich Hansen, Vice President, Discovery Technologies, **Revolution Medicines**

11:50am Wellness Break

Get-up and have a stretch before the next session begins

11:55am Case Study - **Mapping the Genome and the Signalome: CAMP4 Therapeutics**

- Hear about how CAMP4 are providing new insights in multiple therapeutic areas including the brain and liver diseases through their Gene Circuitry Platform™
- Discussion will focus on how this platform, along with next-generation sequencing and machine learning is used to generate Gene Circuitry Maps™ which can identify pathways and druggable targets for any gene of interest
- Hear how this technology is systematizing target discovery and revolutionising drug development

Josh Mandel-Brehm, Chief Executive Officer, **CAMP4 Therapeutics**

questions to the group or simply listen in to the conversation, the choice is yours. Kickstarter discussions include:

- Defining an appropriate IP strategy for multiple undruggable approaches, including patents and trademarks
- How to avoid common mistakes related to IP strategies
- How to align IP strategies and partnership strategies
- Can we learn anything regarding IP from other industries?
- What are the key points to remember when protecting innovation in this industry?

Steve Bossone, Chief Intellectual Property Officer, **Alnylam Pharmaceuticals**

Tamara Kale, Associate General Counsel, Intellectual Property, **Revolution Medicines**

12:15pm Wellness Break

Get-up and have a stretch before the next session begins.

Location: **Sessions**

12:20pm-1:15pm Strategically Focused Panel & Interactive Q&A - **What's The Next Horizon in Undruggability?**

With exciting scientific research and pharma-biotech collaborations in the field of undruggability, increasing at an exponential rate, there will be many key learnings from this Forum that need to be implemented. This final Q&A panel session will be a chance to tap into the minds of the leading minds who are trailblazing the path for unlocking the undruggable.

- Which targets have the potential to become 'the next RAS'?
- Which approaches or technologies have the best opportunity or will have the greatest impact?
- Taking it into the clinic: When will we see more clinical trials and proof-of-concept studies coming to fruition?
- Do we expect to see more pharma-biotech partnerships being established in the near future?
- What can we expect to see progress within the next few years?

Lawrence Hamann, Head, Drug Discovery Sciences, **Takeda**

Josh Mandel-Brehm, Chief Executive Officer, **CAMP4 Therapeutics**

David Hepworth, Vice President, Inflammation and Immunology Medicinal Chemistry, **Pfizer**

Jennifer Petter, Founder and Chief Scientific Officer, **Arrakis Therapeutics**

Location: **Sessions**

12:50pm **Open Q&A with Speakers**

This is your chance to pose your burning questions to the expert panellists.

Actively or passively take part in this session.

Lawrence Hamann, Head, Drug Discovery Sciences, **Takeda**

Josh Mandel-Brehm, Chief Executive Officer, **CAMP4 Therapeutics**

David Hepworth, Vice President, Inflammation and Immunology Medicinal Chemistry, **Pfizer**

Jennifer Petter, Founder and Chief Scientific Officer, **Arrakis Therapeutics**

1:15pm **Close of the Undruggable Leaders Virtual Forum 2020**

Roll straight into the rest of your Wednesday, with no flight to catch!